Sex, age | Risk factors | Previous topical treatment | Microbiological identification | Cause of surgery | Hospitalisation time (days) | Final visual acuity (logMAR) |
Therapeutic penetrating keratoplasty | ||||||
M, 69 | Neurotrophic keratitis | – | Moraxella nonliquefaciens | Impending perforation | 14 | LP |
F, 78 | Diabetes, chemotherapy | DXM | Moraxella spp, Corynebacterium spp | Perforation | 4 | NLP |
M, 75 | Palpebral malposition in Lyell’s syndrome | – | Streptococcus pneumoniae, CoNS | Perforation | 6 | NLP |
F, 27 | Intracorneal rings (D3) | – | S. pneumoniae | Impending perforation | 12 | 0.40 |
M, 65 | Diabetes | – | M. nonliquefaciens | Perforation | 5 | NLP |
M, 24 | Penetrating keratoplasty (Y14) | DXM, tobramycin | Pseudomonas aeruginosa | Graft dehiscence | 5 | 0.20 |
F, 77 | Soft contact lens | Azithromycin | P. aeruginosa | Perforation | 13 | LP |
M, 45 | Penetrating keratoplasty (Y2), interferon | DXM, ciclosporin | Pseudomonas stutzeri | Impending perforation | 36 | 2 |
M, 45 | Graves’ exophthalmos, steroids | – | M. nonliquefaciens | Perforation | 13 | 2.30 |
M, 84 | Palpebral malposition with trichiasis, diabetes | Picloxydine | S. pneumoniae, Klebsiella pneumoniae | Perforation | 34 | LP |
F, 79 | Penetrating keratoplasty (Y5, Y2) | – | CoNS | Perforation | 17 | LP |
M, 57 | Ocular trauma | Fortified antibiotic | – | Perforation | 13 | 2 |
M, 78 | Neurotrophic keratitis, cognitive disorders | – | CoNS, Corynebacterium striatum | Perforation | 18 | LP |
Evisceration | ||||||
M, 35 | Vernal keratoconjunctivitis, LASIK (Y15) | Moraxella lacunata | Phthisis | 14 | NLP | |
M, 85 | Ocular trauma, hemopathy | S. pneumoniae | Endophthalmitis, cellulitis | 9 | NLP | |
F, 55 | Diabetes | Streptococcus dysgalactiae spp | Endophthalmitis, cellulitis | 14 | NLP |
CoNS, coagulase-negative staphylococci; D, day; DXM, dexamethasone; F, female; LP, light perception; M, male; NLP, no light perception; Y, year.